SCHEMBL6879272

SCHEMBL6879272

CC1(CSc2ccc(-c3ccc(C#N)cc3)cc2)NC(=O)NC1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP14 P50281 2/20 0.38
MMP13 P45452 1/20 0.38
MAOB P27338 6/20 0.37
MAOA P21397 5/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 2/20 0.37
KDM4E B2RXH2 1/20 0.37
HPGD P15428 1/20 0.37
MAPK1 P28482 1/20 0.37
HSD17B10 Q99714 1/20 0.37
PGR P06401 2/20 0.35
NOTUM Q6P988 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
DDB1 Q16531 1/20 0.35
CRBN Q96SW2 1/20 0.35
KIF11 P52732 1/20 0.34
MMP3 P08254 2/20 0.33
MMP2 P08253 2/20 0.33
MMP9 P14780 1/20 0.33
MMP8 P22894 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7199008 1.00 MMP14 (0.38) MMP14MMP13MAOBMAOASMN1; SMN2
SCHEMBL6841100 0.83 ALDH1A1 (0.46) SMN1; SMN2ALDH1A1NPSR1MMP3MMP2
SCHEMBL12378669 0.81 ALDH1A1 (0.42) SMN1; SMN2ALDH1A1NPSR1MMP2MMP9
SCHEMBL12378821 0.79 ADAMTS5 (0.43) MMP14MMP13MAOBMAOASMN1; SMN2
SCHEMBL6210406 0.79 ADAMTS5 (0.43) MMP14MMP13MAOBMAOASMN1; SMN2
SCHEMBL6876082 0.78 MMP13 (0.47) MMP14MMP13SMN1; SMN2ALDH1A1KDM4E
SCHEMBL941823 0.76 MMP13 (0.46) MMP14MMP13SMN1; SMN2ALDH1A1KDM4E
SCHEMBL941821 0.75 MMP2 (0.49) MMP14MMP13SMN1; SMN2NOTUMNPSR1
SCHEMBL2872428 0.70 POLB (0.52) MMP14MMP13SMN1; SMN2ALDH1A1KDM4E
SCHEMBL2872659 0.69 GRIA1 (0.46) MMP13MMP3MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147573-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-29 US disclosed
US-20040106659-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106659-A1 Metalloproteinase inhibitors MMP9, TIMP3, MMP11 MMP14 6/4885MMP13 11/4885MAOB 270/4885
US-20040147573-A1 Metalloproteinase inhibitors MMP12, MMP7, MMP10 MMP14 10/4885MMP13 19/4885MAOB 123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.